Baiyunshan Pharmaceutical Gets Green Light to Proceed to Phase II of BYS10 Tablets Trial
MT Newswires Live
Sep 16
Guangzhou Baiyunshan Pharmaceutical (SHA:600332, HKG:0874), through its division Guangzhou Baiyunshan Pharmaceutical General Factory, obtained approval from China's National Medical Products Administration to proceed to phase II of its BYS10 tablets clinical trial, according to a Shanghai bourse disclosure on Wednesday.
The approval was given after Phase I trials showed the drug's safety and efficacy.
The trials are part of the pharmaceutical company's application to market the drug, which is being tested as a treatment of advanced solid tumors, including non-small cell lung cancer and medullary thyroid carcinoma.
The company already invested 146.1 million yuan into the research and development of the drug.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.